.Johnson & Johnson's deprioritization of its infectious health condition pipe has actually claimed yet another target in the form of its dengue virus vaccine mosnodenvir.Mosnodenvir is created to shut out communications between pair of dengue virus healthy proteins. The vaccination survived J&J's decision in 2014 to combine its own transmittable health condition and vaccine procedures, which found the likes of a late-stage respiratory system syncytial infection course dropped from the Big Pharma's pipeline and also an E. coli vaccine sold to Sanofi.Mosnodenvir has had a tough time in the medical clinic, with J&J ending one litigation as a result of the effect of COVID-19 on registration and also stopping briefly employment in an additional study in 2022. However the devotion to mosnodenvir looked to repay in October 2023, when the vaccine was shown to cause a dose-dependent antiviral effect on the detectability as well as onset of dengue infection serotype 3 in a phase 2 test.
That records decline doesn't show up to have actually sufficed to save mosnodenvir for long, along with the Big Pharma revealing this morning that it is discontinuing a follow-up phase 2 field study. The decision is actually associated with a "key reprioritization of the company's pandemic health conditions R&D portfolio," incorporated J&J, which stressed that no safety and security issues had actually been actually determined." Johnson & Johnson will certainly remain to sustain the fight against dengue through sharing study leads along with the medical community in the future," the pharma said in the release.J&J had actually been actually acquiring dengue for over a decade, featuring introducing a Satellite Facility for Global Health And Wellness Breakthrough at the Duke-NUS Medical College in Singapore in 2022. The center has been actually paid attention to speeding up early-stage discovery study to "resolve the increasing difficulty of flaviviruses" like dengue as well as Zika.